You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm reported revenues of $126.0 million for the three-month period ended Dec. 31, 2020, up from $106.9 million in the same period last year.
The partnership will help customers make evidence-based decisions regarding trial designs, companion diagnostics, and drug repurposing.
The firm will consolidate its businesses in newly-built headquarters in Fort Myers, Florida, which it plans to occupy around September.
Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.
The firm will use the proceeds for general corporate purposes and to possibly acquire or invest in complementary businesses and technology.
BTIG highlighted the firm's cancer test portfolio, as well as its growing position in the liquid biopsy and minimal residual disease testing space.
Clinical test volume and requisitions received each grew about 2 percent year over year, while the average revenue per test fell 3 percent.
New offerings from the oncology testing company include Inivita's InvisionFirst-Lung test and the NeoLab solid tumor test.
The decline was largely due to decreased testing volumes as a result of the COVID-19 pandemic, although there was improvement in pharma services.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.
